Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etirinotecan Pegol in Refractory Brain Metastases
NCT02312622Phase 2Completed
- Sponsor
- Joel Neal
- Start
- Aug 2015
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of crizanlizumab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, sponsored by Joel Neal. Started Aug 2015; status: completed.
02
Drugs
crizanlizumab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)breast cancer
Beyond the preview
Go deeper on NCT02312622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312622.